Aristoteles Achilles Nikolaus Giagounid

List of Publications by Year
in descending order

288 papers	17,544 citations	18436 62 h-index	14702 127 g-index
300 all docs	300 docs citations	300 times ranked	11176 citing authors

#	Article	IF	Citations
1	Evolution of severe (transfusionâ€dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophageâ€associated failure of the eythropoietic niche. British Journal of Haematology, 2022, , .	1.2	3
2	Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e874-e883.	0.2	3
3	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratificationâ€"an approach to classification of patients with t-MDS. Leukemia, 2021, 35, 835-849.	3.3	54
4	Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. Leukemia, 2021, 35, 897-900.	3.3	12
5	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia, 2021, 35, 2517-2525.	3.3	40
6	Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). Annals of Hematology, 2021, 100, 1463-1471.	0.8	1
7	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1426-1436.	0.8	49
8	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). Journal of Clinical Oncology, 2021, 39, 3318-3327.	0.8	44
9	Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center. Leukemia Research, 2021, 108, 106611.	0.4	4
10	Treatment of Combined Autoimmune Neutropenia and Immune Thrombocytopenia with Methotrexate. Acta Haematologica, 2020, 143, 89-90.	0.7	3
11	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia, 2020, 34, 1182-1186.	3.3	39
12	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 Ã— 2, Phase II Trial. Journal of Clinical Oncology, 2020, 38, 257-270.	0.8	63
13	Impact of complete surgical resection on outcome in aggressive nonâ€Hodgkin lymphoma treated with immunochemotherapy. Cancer Medicine, 2020, 9, 8386-8396.	1.3	5
14	Where Does Morphology Fit in Myelodysplastic Syndrome Diagnosis in the Era of Molecular Testing?. Hematology/Oncology Clinics of North America, 2020, 34, 321-331.	0.9	2
15	Baseline and interim PETâ€based outcome prediction in peripheral Tâ€cell lymphoma: A subgroup analysis of the PETAL trial. Hematological Oncology, 2020, 38, 244-256.	0.8	18
16	Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leukemia and Lymphoma, 2020, 61, 1475-1483.	0.6	4
17	Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2019, 25, 6976-6985.	3.2	55
18	Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a PhaseÂIIIÂTrial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 213-219.e4.	0.2	3

#	Article	IF	Citations
19	Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood, 2019, 133, 1020-1030.	0.6	98
20	Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the â€œPositron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomasâ€•(PETAL) trial. Annals of Hematology, 2019, 98, 897-907.	0.8	24
21	Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report. Case Reports in Oncology, 2018, 11, 109-113.	0.3	6
22	A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-Î± in anemic patients with low-risk MDS. Leukemia, 2018, 32, 2648-2658.	3.3	100
23	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematology,the, 2018, 5, e117-e126.	2.2	81
24	The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 136-144.e7.	0.2	15
25	The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q). Blood Cancer Journal, 2018, 8, 90.	2.8	8
26	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	1.5	3
27	Positron Emission Tomographyâ€“Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2018, 36, 2024-2034.	0.8	176
28	Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood, 2018, 132, 1225-1240.	0.6	168
29	Lenalidomide for the Treatment of MDS. Hematologic Malignancies, 2018, , 119-129.	0.2	1
30	Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial. Blood, 2018, 132, 4045-4045.	0.6	15
31	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. Blood, 2018, 132, 720-720.	0.6	4
32	Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) â€” Preliminary Blinded Analysis of the European Sintra-REV Trial. Blood, 2018, 132, 468-468.	0.6	3
33	Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM).. Journal of Clinical Oncology, 2018, 36, 8016-8016.	0.8	1
34	Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.. Journal of Clinical Oncology, 2018, 36, 7018-7018.	0.8	0
35	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. Blood, 2018, 132, 3103-3103.	0.6	0
36	New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. Leukemia Research, 2017, 57, 78-84.	0.4	30

#	Article	IF	Citations
37	Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. Journal of Medical Genetics, 2017, 54, 640-650.	1.5	0
38	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Annals of Hematology, 2017, 96, 887-894.	0.8	7
39	Long-term survival of sorafenib-treated FLT3-ITDâ€“positive acute myeloid leukaemia patients relapsingÂafter allogeneic stem cell transplantation. European Journal of Cancer, 2017, 86, 233-239.	1.3	59
40	Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncology, The, 2017, 18, 1338-1347.	5.1	241
41	Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature. Case Reports in Oncology, 2017, 10, 638-643.	0.3	11
42	Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). Journal of Hematology and Oncology, 2017, 10, 131.	6.9	8
43	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 2017, 8, 73483-73500.	0.8	153
44	Current treatment algorithm for the management of lower-risk MDS. Hematology American Society of Hematology Education Program, 2017, 2017, 453-459.	0.9	24
45	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. Blood, 2017, 130, 721-721.	0.6	20
46	Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes. Haematologica, 2016, 101, e177-e181.	1.7	10
47	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2016, 34, 2988-2996.	0.8	190
48	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusionâ€“dependent anemia and thrombocytopenia. BMC Hematology, 2016, 16, 12.	2.6	31
49	Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia, 2016, 30, 1956-1959.	3.3	55
50	Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox. Oncology Research and Treatment, 2016, 39, 384-387.	0.8	2
51	Causes of death in 2877 patients with myelodysplastic syndromes. Annals of Hematology, 2016, 95, 937-944.	0.8	74
52	Activity of the oral mitogenâ€activated protein kinase kinase inhibitor trametinib in <scp>RAS</scp>â€mutant relapsed or refractory myeloid malignancies. Cancer, 2016, 122, 1871-1879.	2.0	113
53	Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia, 2016, 30, 1580-1582.	3.3	30
54	Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia, 2016, 30, 1230-1236.	3.3	43

#	Article	IF	Citations
55	Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. Leukemia, 2016, 30, 1781-1784.	3.3	13
56	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Annals of Hematology, 2016, 95, 191-199.	0.8	84
57	Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia. Leukemia, 2016, 30, 555-561.	3.3	47
58	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 112-112.	0.6	2
59	Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with T Cell Lymphomas Participating in the PETAL Trial. Blood, 2016, 128, 185-185.	0.6	9
60	Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial. Blood, 2016, 128, 1857-1857.	0.6	7
61	Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood, 2016, 128, 225-225.	0.6	2
62	Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. Blood, 2016, 128, 3168-3168.	0.6	9
63	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. Blood, 2016, 128, 589-589.	0.6	11
64	Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).. Journal of Clinical Oncology, 2016, 34, 7014-7014.	0.8	0
65	Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).. Journal of Clinical Oncology, 2016, 34, 7061-7061.	0.8	0
66	Luspatercept Response in ESA-NaÃ¯ve/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 5551-5551.	0.6	0
67	CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q). British Journal of Haematology, 2015, 171, 210-214.	1.2	19
68	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica, 2015, 100, 205-213.	1.7	20
69	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a <scp>G</scp>erman diagnostic study in comparison with an international control group. Genes Chromosomes and Cancer, 2015, 54, 809-817.	1.5	8
70	Where Does Lenalidomide Fit in Non-del(5q) MDS?. Current Hematologic Malignancy Reports, 2015, 10, 303-308.	1.2	3
71	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematology,the, 2015, 2, e417-e426.	2.2	64
72	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nature Communications, 2015, 6, 5901.	5.8	196

#	Article	IF	Citations
73	Change of prognosis of patients with myelodysplastic syndromes during the last 30 years. Leukemia Research, 2015, 39, 679-683.	0.4	19
74	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1691-1699.	5.1	347
75	Impact of selfâ€administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider. European Journal of Haematology, 2015, 94, 169-176.	1.1	9
76	Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). Annals of Hematology, 2015, 94, 2003-2013.	0.8	20
77	Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide. Leukemia Research, 2015, 39, 1292-1298.	0.4	15
78	Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 1669-1669.	0.6	14
79	Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. Blood, 2015, 126, 2862-2862.	0.6	4
80	Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. Blood, 2015, 126, 2863-2863.	0.6	9
81	Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs). Blood, 2015, 126, 2880-2880.	0.6	1
82	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. Blood, 2015, 126, 2891-2891.	0.6	1
83	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 609-609.	0.6	5
84	Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. Blood, 2015, 126, 92-92.	0.6	18
85	Myelodysplastische Syndrome. , 2015, , 1-15.		0
86	Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 4114-4114.	0.6	0
87	Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide. Blood, 2015, 126, 2867-2867.	0.6	0
88	Results of a randomized, doubleâ€blind study of romiplostim versus placebo in patients with low/intermediateâ€1â€“risk myelodysplastic syndrome and thrombocytopenia. Cancer, 2014, 120, 1838-1846.	2.0	149
89	Outcomes in <scp>RBC</scp> transfusionâ€dependent patients with <scp>L</scp>owâ€/<scp>I</scp>ntermediateâ€1â€risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the <scp>MDS</scp>â€004 study. European Journal of Haematology, 2014, 93, 429-438.	1.1	32
90	Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. Leukemia Research, 2014, 38, 57-64.	0.4	68

#	Article	IF	Citations
91	Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Annals of Hematology, 2014, 93, 1-11.	0.8	38
92	Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia, 2014, 28, 1033-1040.	3.3	83
93	Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial. Leukemia, 2014, 28, 2418-2421.	3.3	13
94	Development and validation of a model to predict platelet response to romiplostim in patients with lowerâ€risk myelodysplastic syndromes. British Journal of Haematology, 2014, 167, 337-345.	1.2	19
95	Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. Leukemia, 2014, 28, 696-698.	3.3	18
96	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica, 2014, 99, 1041-1049.	1.7	116
97	Treatment with Romiplostim, a Thrombopoietin-Receptor Agonist, in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Updated Follow-up Results for Acute Myeloid Leukemia (AML) and Survival from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. Blood, 2014, 124, 3276-3276.	0.6	3
98	Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas â€“ a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	30
99	Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). Blood, 2014, 124, 409-409.	0.6	11
100	ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study. Blood, 2014, 124, 411-411.	0.6	12
101	Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial. Blood, 2014, 124, 6-6.	0.6	34
102	Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies. Blood, 2014, 124, 3270-3270.	0.6	0
103	Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial. Blood, 2014, 124, 1920-1920.	0.6	0
104	Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Annals of Hematology, 2013, 92, 191-198.	0.8	72
105	Monosomal karyotype in MDS: explaining the poor prognosis?. Leukemia, 2013, 27, 1988-1995.	3.3	42
106	Identification of Gene Expressionâ€“Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, 3557-3564.	0.8	45
107	Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 2013, 31, 3110-3118.	0.8	290
108	Morphology, cytogenetics and classification of MDS. Best Practice and Research in Clinical Haematology, 2013, 26, 337-353.	0.7	37

#	Article	IF	Citations
109	Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia, 2013, 27, 1229-1235.	3.3	195
110	Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leukemia Research, 2013, 37, 64-70.	0.4	39
111	Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study. Leukemia Research, 2013, 37, 900-906.	0.4	22
112	Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica, 2013, 98, 1856-1864.	1.7	29
113	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus lowâ€dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer, 2013, 119, 2611-2619.	2.0	88
114	Longâ€term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. European Journal of Haematology, 2013, 91, 423-436.	1.1	90
115	Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia, 2013, 27, 1072-1079.	3.3	66
116	Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia, 2013, 27, 1760-1763.	3.3	10
117	Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia, 2013, 27, 1403-1407.	3.3	50
118	Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica, 2013, 98, 208-216.	1.7	176
119	Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group. Blood, 2013, 122, 1452-1452.	0.6	3
120	Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study. Blood, 2013, 122, 1553-1553.	0.6	3
121	Association Between Gene Expression Profiles and Commonly Mutated Genes In The Hematopoietic Stem Cells Of Patients With Myelodysplastic Syndromes. Blood, 2013, 122, 2779-2779.	0.6	1
122	Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide Monotherapy Reveals 82% Cytogenetic Responders With Different Response â€“ , Evolutionary -, and Remission Patterns and No Increased Karyotype Evolution (KE). Blood, 2013, 122, 2783-2783.	0.6	2
123	Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q). Blood, 2013, 122, 390-390.	0.6	2
124	Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia â€” A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy. Blood, 2013, 122, 5214-5214.	0.6	3
125	Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome. Blood, 2013, 122, 2781-2781.	0.6	0
126	Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity. Blood, 2013, 122, 1447-1447.	0.6	0

#	Article	IF	Citations
127	Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study. Blood, 2013, 122, 2753-2753.	0.6	0
128	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. Blood, 2013, 122, 2759-2759.	0.6	0
129	Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004. Blood, 2013, 122, 1538-1538.	0.6	0
130	Use of Romiplostim in a Hemodialysis Patient with Primary Immune Thrombocytopenia. Annals of Pharmacotherapy, 2012, 46, e31-e31.	0.9	4
131	Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia, 2012, 26, 2154-2158.	3.3	19
132	Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. Leukemia, 2012, 26, 1286-1292.	3.3	112
133	Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide. Leukemia, 2012, 26, 356-358.	3.3	25
134	A patient with Fechtner syndrome successfully treated with romiplostim. Thrombosis and Haemostasis, 2012, 107, 590-591.	1.8	17
135	Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood, 2012, 120, 3670-3676.	0.6	55
136	Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia, 2012, 26, 1475-1481.	3.3	58
137	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829.	0.8	584
138	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia, 2012, 26, 2353-2359.	3.3	208
139	Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes. Seminars in Hematology, 2012, 49, 312-322.	1.8	18
140	Introduction: Application of New Therapies to Myelodysplastic Syndrome. Seminars in Hematology, 2012, 49, 285-286.	1.8	0
141	Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia, 2012, 26, 855-858.	3.3	28
142	Healthâ€related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. American Journal of Hematology, 2012, 87, 558-561.	2.0	68
143	Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. International Journal of Hematology, 2012, 96, 26-33.	0.7	20
144	Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the DÃ¼sseldorf Registry on myelodysplastic syndromes. Leukemia Research, 2012, 36, 727-734.	0.4	76

#	Article	IF	Citations
145	Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients â‰¥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial. Blood, 2012, 120, 144-144.	0.6	4
146	Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Blood, 2012, 120, 1503-1503.	0.6	1
147	Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).. Blood, 2012, 120, 2801-2801.	0.6	2
148	CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study. Blood, 2012, 120, 3816-3816.	0.6	2
149	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. Blood, 2012, 120, 421-421.	0.6	9
150	Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.. Blood, 2012, 120, 2826-2826.	0.6	11
151	Activation of the mTOR Signaling Pathway by L-Leucine in RPS14-Deficient Erythroid Cells. Blood, 2012, 120, 171-171.	0.6	1
152	Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53-Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes. Blood, 2012, 120, 921-921.	0.6	0
153	Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups. Blood, 2012, 120, 3801-3801.	0.6	0
154	A Comprehensive Genetic Analysis of MDS Patients From Peripheral Blood Combining FISH- and SNP-Array-Analysis. Blood, 2012, 120, 4926-4926.	0.6	0
155	Safety and Efficacy of a Six Month Full Dose Lenalidomide Consolidation Treatment After First-Line High-Dose Therapy in Patients with Multiple Myeloma. Blood, 2012, 120, 1982-1982.	0.6	0
156	Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.. Blood, 2012, 120, 2804-2804.	0.6	0
157	Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups. Blood, 2012, 120, 1509-1509.	0.6	0
158	Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 433-438.	0.2	50
159	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 2011, 118, 3765-3776.	0.6	424
160	If it ain't broke, don't fix it!. Haematologica, 2011, 96, e44-e44.	1.7	0
161	Marked downâ€regulation of nucleophosminâ€1 is associated with advanced del(5q) myelodysplastic syndrome. British Journal of Haematology, 2011, 155, 272-274.	1.2	6
162	Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia, 2011, 25, 110-120.	3.3	113

#	Article	IF	Citations
163	A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS. Annals of Hematology, 2011, 90, 667-673.	0.8	12
164	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. Journal of Clinical Oncology, 2011, 29, 1963-1970.	0.8	139
165	Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Careâ€"SAKK 33/99. Journal of Clinical Oncology, 2011, 29, 303-309.	0.8	175
166	Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 2011, 29, 1987-1996.	0.8	514
167	Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide. Haematologica, 2011, 96, 319-322.	1.7	18
168	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study. Blood, 2011, 118, 117-117.	0.6	12
169	Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study. Blood, 2011, 118, 119-119.	0.6	2
170	Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes. Blood, 2011, 118, 1704-1704.	0.6	2
171	Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis. Blood, 2011, 118, 1723-1723.	0.6	21
172	A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission. Blood, 2011, 118, 2759-2759.	0.6	2
173	Therapy of Acquired Aplastic Anemia (AA) with Rabbit Antithymocyte Globulin (rATG): A Retrospective Analysis by the Working Group on Non-Malignant Disorders of Hematopoiesis of the German Society of Hematology and Oncology (DGHO),. Blood, 2011, 118, 3434-3434.	0.6	1
174	Final Results From a Phase II Trial with the First in Class Recombinant Polyclonal Antibody Product Rozrolimupab in Primary Immune Thrombocytopenia. Blood, 2011, 118, 527-527.	0.6	3
175	Genetic Response to Lenalidomide in the Circulating Progenitor Cell Compartment of MDS Cohort. Preliminary Results of the Multicenter German LE-MON-5 Study. Blood, 2011, 118, 1721-1721.	0.6	0
176	Induction of p53 and up-regulation of the p53 pathway in the human 5qâ^' syndrome. Blood, 2010, 115, 2721-2723.	0.6	65
177	Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy. Blood, 2010, 116, 2617-2618.	0.6	13
178	Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Annals of Hematology, 2010, 89, 427-428.	0.8	24
179	Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Annals of Hematology, 2010, 89, 365-374.	0.8	74
180	Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Annals of Hematology, 2010, 89, 841-850.	0.8	39

#	Article	IF	Citations
181	Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q). Leukemia, 2010, 24, 1875-1884.	3.3	14
182	Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia, 2010, 24, 1062-1065.	3.3	231
183	Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia, 2010, 24, 756-764.	3.3	250
184	Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Annals of Oncology, 2010, 21, 120-125.	0.6	63
185	Lenalidomide reexposure After Short Interruption In Del(5q) MDS Patients at Relapse of Transfusion Dependence. Blood, 2010, 116, 2923-2923.	0.6	1
186	Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation. Blood, 2010, 116, 3314-3314.	0.6	4
187	A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities â€“ Interim Results of the â€œAZALEâ€•Trial. Blood, 2010, 116, 4000-4000.	0.6	2
188	Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC). Blood, 2010, 116, 569-569.	0.6	1
189	Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q. Blood, 2010, 116, 30-30.	0.6	0
190	Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk. Blood, 2010, 116, 4031-4031.	0.6	1
191	Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance. Blood, 2010, 116, 4022-4022.	0.6	0
192	Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?. Blood, 2010, 116, 4008-4008.	0.6	0
193	Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells. Blood, 2010, 116, 298-298.	0.6	1
194	An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. Journal of Antimicrobial Chemotherapy, 2009, 64, 1274-1281.	1.3	135
195	Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome. International Journal of Hematology, 2009, 89, 173-187.	0.7	25
196	12 Updated cytogenetic risk features in MDS â€“ present state. Leukemia Research, 2009, 33, S9-S10.	0.4	7
197	C006 Detailed morphologic findings in 2773 patients with myelodysplastic syndromes. Leukemia Research, 2009, 33, S34.	0.4	0
198	C007 Validation of the WHO proposals for the classification of unclassifiable myelodysplastic syndromes. Leukemia Research, 2009, 33, S35.	0.4	0

#	Article	IF	Citations
199	P007 Attempts to define a No Risk subgroup in MDS by examining relative survival in well known scoring systems. Leukemia Research, 2009, 33, S61-S62.	0.4	0
200	P018 Host related features explain heterogeneity in risk groups of disease related scoring systems in MDS. Leukemia Research, 2009, 33, S68.	0.4	0
201	P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q). Leukemia Research, 2009, 33, S74.	0.4	0
202	P098 Detection and management of iron overload in MDS: a European survey. Leukemia Research, 2009, 33, S116.	0.4	0
203	P115 Long-term transfusion independence in del(5q) patients despite discontinuation of lenalidomide. Leukemia Research, 2009, 33, S126-S127.	0.4	0
204	P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA). Leukemia Research, 2009, 33, S133-S134.	0.4	0
205	Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. British Journal of Haematology, 2009, 146, 86-90.	1.2	25
206	Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leukemia Research, 2009, 33, 1024-1028.	0.4	42
207	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, The, 2009, 10, 223-232.	5.1	2,404
208	Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving Romiplostim or Medical Standard of Care.. Blood, 2009, 114, 1311-1311.	0.6	1
209	Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.. Blood, 2009, 114, 2060-2060.	0.6	7
210	Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL trial): Correlation between Clinical Variables and PET Parameters.. Blood, 2009, 114, 2695-2695.	0.6	1
211	Cytogenetic Risk Features in MDS-Update and Present State.. Blood, 2009, 114, 2772-2772.	0.6	5
212	Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.. Blood, 2009, 114, 3800-3800.	0.6	5
213	Detection and Treatment of Iron Overload in Red Blood Cell (RBC) Transfusion-Dependent Myelodysplastic Syndromes (MDS): A European Survey.. Blood, 2009, 114, 4830-4830.	0.6	2
214	Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.. Blood, 2009, 114, 485-485.	0.6	4
215	Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).. Blood, 2009, 114, 945-945.	0.6	6
216	Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.. Blood, 2009, 114, 3818-3818.	0.6	0

#	Article	IF	Citations
217	Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Annals of Hematology, 2008, 87, 345-352.	0.8	76
218	Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leukemia Research, 2008, 32, 33-37.	0.4	34
219	Haploinsufficiency of RPS14 in 5qâ^' syndrome is associated with deregulation of ribosomalâ€•and translationâ€•related genes. British Journal of Haematology, 2008, 142, 57-64.	1.2	91
220	Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2008, 26, 5943-5949.	0.8	114
221	Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica, 2008, 93, 994-1000.	1.7	42
222	Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood, 2008, 112, 226-226.	0.6	52
223	New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics. Blood, 2008, 112, 2688-2688.	0.6	2
224	Characteristics of Disease Progression in 3213 Patients with Myelodysplastic Syndrome. Blood, 2008, 112, 2689-2689.	0.6	1
225	The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts. PLoS ONE, 2008, 3, e1970.	1.1	113
226	Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q). Blood, 2008, 112, 3641-3641.	0.6	0
227	From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1307-1312.	3.3	91
228	Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2007, 25, 3503-3510.	0.8	969
229	Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica, 2007, 92, 974-977.	1.7	72
230	Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood, 2007, 110, 3365-3373.	0.6	190
231	Decitabine dosage in myelodysplastic syndromes. Blood, 2007, 110, 1082-1083.	0.6	12
232	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, 2007, 110, 4385-4395.	0.6	719
233	Clinical features and prognosis of patients with myelodysplastic syndromes. Cancer Treatment Reviews, 2007, 33, S15-S18.	3.4	4
234	Current treatment strategies in low-risk myelodysplastic syndromes. Cancer Treatment Reviews, 2007, 33, S19-S24.	3.4	2

#	Article	IF	Citations
235	Bone marrow morphology and classification systems in myelodysplastic syndromes. Cancer Treatment Reviews, 2007, 33, S2-S5.	3.4	2
236	Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. Clinical Leukemia, 2007, 1, 353-356.	0.2	7
237	Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer, 2007, 109, 2068-2076.	2.0	214
238	Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer, 2007, 110, 345-352.	2.0	113
239	Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. British Journal of Haematology, 2007, 138, 399-400.	1.2	12
240	Gene expression profiling of CD34⁺ cells in patients with the 5qâ^' syndrome. British Journal of Haematology, 2007, 139, 578-589.	1.2	146
241	Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS).. Blood, 2007, 110, 821-821.	0.6	3
242	Prognostic Factors in Treatment-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemia (t-AML).. Blood, 2007, 110, 2451-2451.	0.6	1
243	Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. New England Journal of Medicine, 2006, 355, 1456-1465.	13.9	1,251
244	X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells, Molecules, and Diseases, 2006, 37, 40-45.	0.6	38
245	Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood, 2006, 108, 337-345.	0.6	198
246	Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. British Journal of Haematology, 2006, 132, 162-167.	1.2	30
247	The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia, 2006, 20, 1319-1321.	3.3	92
248	The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia, 2006, 20, 2060-2061.	3.3	71
249	Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Annals of Hematology, 2006, 86, 133-137.	0.8	30
250	Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies. Clinical Cancer Research, 2006, 12, 5-10.	3.2	126
251	New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.. Blood, 2006, 108, 248-248.	0.6	3
252	Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.. Blood, 2006, 108, 251-251.	0.6	11

#	Article	IF	Citations
253	Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.. Blood, 2006, 108, 252-252.	0.6	4
254	A Transcriptional Signature Distinguishing Short and Long-Term Surviving Patients with MDS.. Blood, 2006, 108, 4866-4866.	0.6	0
255	High-Resolution Genomic Profiling of Myelodysplasia (MDS) by Microarray Comparative Genomic Hybridization (CGH).. Blood, 2006, 108, 2645-2645.	0.6	0
256	Expression Profiling of CD34+ Cells in Patients with Myelodysplastic Syndromes: Involvement of Interferon-Stimulated Genes and Correlation to FAB Subtype and Karyotype.. Blood, 2006, 108, 2626-2626.	0.6	0
257	Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica, 2006, 91, 1596-604.	1.7	116
258	Breast Cancer Metastasis to the Aortic Vessel Wall. Oncology Research and Treatment, 2005, 28, 369-369.	0.8	4
259	Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia, 2005, 19, 2223-2231.	3.3	153
260	Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31â€“q33 with a combination of all-trans-retinoic acid and tocopherol-Î±: a phase II study. Annals of Hematology, 2005, 84, 389-394.	0.8	26
261	Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Annals of Hematology, 2005, 84, 569-571.	0.8	71
262	Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clinical Chemistry and Laboratory Medicine, 2005, 43, 133-40.	1.4	41
263	Autoimmune Disorders in Two Patients with Myelodysplastic Syndrome and 5q Deletion. Acta Haematologica, 2005, 113, 146-149.	0.7	17
264	The Nonsteroidal Anti-Inflammatory Drug Exisulind Selectively Induces Apoptosis via JNK in Secondary Acute Myeloid Leukemia after Myelodysplastic Syndrome. Cell Cycle, 2005, 4, 812-817.	1.3	10
265	Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.. Blood, 2005, 106, 372-372.	0.6	17
266	A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.. Blood, 2005, 106, 788-788.	0.6	18
267	Sequential Cytogenetic Analyses of 577 Patients with Myelodysplastic Syndromes: Correlations between Initial Karyotype, Cytogenetic Dynamics, and Clinical Course.. Blood, 2005, 106, 2531-2531.	0.6	2
268	Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia, 2004, 18, 113-119.	3.3	191
269	Early plasmacytoid dendritic cell leukemia/lymphoma coexpressing myeloid antigenes. Annals of Hematology, 2004, 83, 716-721.	0.8	13
270	The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.. Blood, 2004, 104, 1448-1448.	0.6	0

#	Article	IF	Citations
271	Fournier's gangrene. Annals of Hematology, 2003, 82, 531-532.	0.8	0
272	Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leukemia Research, 2003, 27, 397-404.	0.4	42
273	Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. European Journal of Haematology, 2002, 68, 210-216.	1.1	34
274	Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. European Journal of Haematology, 2002, 69, 95-100.	1.1	113
275	Testicular infiltration in acute myeloid leukemia with complex karyotype including t(8;21). Annals of Hematology, 2002, 81, 115-118.	0.8	4
276	Evaluating the prognosis of patients with myelodysplastic syndromes. Annals of Hematology, 2002, 81, 485-497.	0.8	34
277	Epidemiological Features of Myelodysplastic Syndromes: Results From Regional Cancer Surveys and Hospital-Based Statistics. International Journal of Hematology, 2001, 73, 405-410.	0.7	80
278	Acute basophilic leukemia. European Journal of Haematology, 2001, 67, 72-76.	1.1	27
279	Prevention of postsplenectomy sepsis. The Hematology Journal, 2001, 2, 67-67.	2.0	3
280	Evaluation of Neutropenic Fever: Value of Serum and Plasma Parameters in Clinical Practice. Chemotherapy, 2000, 46, 77-85.	0.8	26
281	Acute promyelocytic leukemia and pregnancy. European Journal of Haematology, 2000, 64, 267-271.	1.1	36
282	Patents for intellectual property. Lancet, The, 2000, 356, 2016.	6.3	2
283	Dyshematopoiesis in De Novo Acute Myeloid Leukemia: Cell Biological Features and Prognostic Significance. Leukemia and Lymphoma, 1998, 29, 523-531.	0.6	9
284	Lymphoid Myelofibrosis Associated with High Grade B Cell Lymphoma of the Liver: Morphological, Cytogenetic, and Clinical Features. Leukemia and Lymphoma, 1997, 26, 197-204.	0.6	3
285	Terathanasia or teratothanasia?. Lancet, The, 1997, 350, 1712.	6.3	0
286	Pseudomonas aeruginosa blepharoconjunctivitis during cytoreductive chemotherapy in a woman with acute lymphocytic leukemia. Annals of Hematology, 1997, 75, 121-123.	0.8	19
287	Improved prophylaxis against overwhelming postsplenectomy infections. European Journal of Haematology, 1997, 59, 329-330.	1.1	1
288	Pathologic rupture of the spleen in hematologic malignancies: two additional cases. Annals of Hematology, 1996, 73, 297-302.	0.8	99